Lynparza
Lynparza
$0.00
Lynparza (olaparib) is an oral targeted cancer therapy classified as a PARP inhibitor. It is used to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA gene mutations.
Delivery
5-7 day
In Stock
Yes
Guaranteed
Source Canadian PharmacyLynparza (generic name: olaparib) is a prescription medicine that belongs to a class of drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. PARP is an enzyme that helps repair damaged DNA in cells. By blocking PARP, Lynparza prevents cancer cells with DNA repair defects—such as those caused by BRCA1 or BRCA2 mutations—from repairing themselves, leading to cancer cell death.
It is approved for the treatment of:
-
Advanced ovarian cancer in patients with BRCA mutations or after response to platinum-based chemotherapy.
-
Breast cancer with germline BRCA mutations, particularly HER2-negative cases.
-
Pancreatic cancer with germline BRCA mutations after chemotherapy.
-
Prostate cancer with BRCA or other DNA repair gene mutations.
Lynparza is taken orally in tablet form, usually twice daily. Common side effects include fatigue, nausea, anemia, decreased appetite, vomiting, diarrhea, and low blood counts.
As a targeted therapy, it offers a personalized treatment option for patients whose tumors have specific genetic vulnerabilities, making it a key drug in precision oncology.